Annexon Expands Board of Directors with Appointment of Commercial Executive William “BJ” Jones
Annexon, a biopharmaceutical company listed on Nasdaq under the ticker ANNX, has appointed William “BJ” Jones to its board of directors. Mr. Jones brings 30 years of experience in the biotechnology industry, focusing on U.S. and global commercial operations.
According to Douglas Love, Annexon's CEO, Mr. Jones's expertise will be important as the company advances its late-stage clinical therapies, specifically ANX005 for Guillain-Barré Syndrome and ANX007 for geographic atrophy, toward commercialization.
Mr. Jones currently serves as the Chief Commercial Officer at NewAmsterdam Pharma and has a history of successful product launches, including roles at Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, and NitroMed. He has been involved in the commercialization of major brands like Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil®, and Excedrin Migraine®.
Mr. Jones holds an M.B.A from Stanford Graduate School of Business and an M.S. in Industrial Engineering from Texas A&M University.
Annexon, un'azienda biofarmaceutica quotata al Nasdaq con il ticker ANNX, ha nominato William “BJ” Jones nel suo consiglio di amministrazione. Il signor Jones porta con sé 30 anni di esperienza nel settore della biotecnologia, concentrandosi sulle operazioni commerciali negli Stati Uniti e a livello globale.
Secondo Douglas Love, CEO di Annexon, l'expertise del signor Jones sarà fondamentale mentre l'azienda progredisce nelle sue terapie cliniche in fase avanzata, in particolare ANX005 per la Sindrome di Guillain-Barré e ANX007 per l'atrofia geografica, verso la commercializzazione.
Attualmente, il signor Jones ricopre il ruolo di Chief Commercial Officer presso NewAmsterdam Pharma e ha una storia di lanci di prodotti di successo, inclusi ruoli presso Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim e NitroMed. È stato coinvolto nella commercializzazione di marchi importanti come Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® e Excedrin Migraine®.
Il signor Jones ha conseguito un M.B.A presso la Stanford Graduate School of Business e un M.S. in Ingegneria Industriale presso la Texas A&M University.
Annexon, una empresa biofarmacéutica que cotiza en Nasdaq bajo el símbolo ANNX, ha nombrado a William “BJ” Jones en su junta directiva. El Sr. Jones aporta 30 años de experiencia en la industria de la biotecnología, centrándose en operaciones comerciales en EE. UU. y a nivel global.
Según Douglas Love, CEO de Annexon, la experiencia del Sr. Jones será importante a medida que la compañía avance en sus terapias clínicas en etapa avanzada, específicamente ANX005 para el Síndrome de Guillain-Barré y ANX007 para la atrofia geográfica, rumbo a la comercialización.
Actualmente, el Sr. Jones se desempeña como Director Comercial en NewAmsterdam Pharma y tiene un historial de lanzamientos de productos exitosos, incluidos roles en Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim y NitroMed. Ha estado involucrado en la comercialización de marcas importantes como Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® y Excedrin Migraine®.
El Sr. Jones posee un M.B.A de la Stanford Graduate School of Business y un M.S. en Ingeniería Industrial de la Universidad Texas A&M.
Annexon은 ANNX라는 티커로 Nasdaq에 상장된 생명공학 회사로, William “BJ” Jones를 이사회에 임명했습니다. Jones 씨는 30년의 생명공학 산업 경력을 보유하고 있으며, 미국 및 글로벌 상업 운영에 중점을 두고 있습니다.
Douglas Love Annexon CEO에 따르면, Jones 씨의 전문성은 회사가 임상 치료법인 ANX005 (길랭-바레 증후군 치료)와 ANX007 (지리적 위축 치료)를 상업화하는 데 중요한 역할을 할 것입니다.
Jones 씨는 현재 NewAmsterdam Pharma의 최고상업책임자(Chief Commercial Officer)로 재직 중이며, Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim, NitroMed 등 여러 곳에서 성공적인 제품 출시를 이끌었습니다. 그는 Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil®, Excedrin Migraine®와 같은 주요 브랜드의 상업화에도 참여했습니다.
Jones 씨는 Stanford Graduate School of Business에서 M.B.A.를, Texas A&M University에서 산업공학 석사(M.S.)를 취득하였습니다.
Annexon, une entreprise biopharmaceutique cotée au Nasdaq sous le ticker ANNX, a nommé William “BJ” Jones au sein de son conseil d'administration. M. Jones apporte 30 ans d'expérience dans l'industrie biotechnologique, en se concentrant sur les opérations commerciales aux États-Unis et à l'échelle mondiale.
Selon Douglas Love, PDG d'Annexon, l'expertise de M. Jones sera importante alors que l'entreprise avance dans ses thérapies cliniques de stade avancé, en particulier ANX005 pour le syndrome de Guillain-Barré et ANX007 pour l'atrophie géographique, vers la commercialisation.
M. Jones occupe actuellement le poste de directeur commercial chez NewAmsterdam Pharma et possède un historique de lancements de produits réussis, y compris des rôles chez Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim et NitroMed. Il a participé à la commercialisation de grandes marques telles que Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® et Excedrin Migraine®.
M. Jones est titulaire d'un M.B.A de la Stanford Graduate School of Business et d'un M.S. en ingénierie industrielle de l'Université Texas A&M.
Annexon, ein biopharmazeutisches Unternehmen, das an der Nasdaq unter dem Ticker ANNX notiert ist, hat William “BJ” Jones in seinen Vorstand berufen. Herr Jones bringt 30 Jahre Erfahrung in der Biotechnologiebranche mit, mit dem Schwerpunkt auf den kommerziellen Aktivitäten in den USA und weltweit.
Laut Douglas Love, dem CEO von Annexon, wird die Expertise von Herrn Jones entscheidend sein, während das Unternehmen seine klinischen Therapien in der späten Phase vorantreibt, insbesondere ANX005 für das Guillain-Barré-Syndrom und ANX007 für geografische Atrophie auf den Weg zur Kommerzialisierung.
Herr Jones ist derzeit Chief Commercial Officer bei NewAmsterdam Pharma und hat eine Geschichte erfolgreicher Produkteinführungen, einschließlich Positionen bei Biohaven Pharmaceuticals, Takeda Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, Boehringer-Ingelheim und NitroMed. Er war an der Kommerzialisierung bedeutender Marken wie Nurtec® ODT, Abilify®, Farxiga®, Pradaxa®, BiDil® und Excedrin Migraine® beteiligt.
Herr Jones hat einen MBA von der Stanford Graduate School of Business und einen M.S. in Maschinenbau von der Texas A&M University.
- Appointment of William “BJ” Jones to the board of directors brings 30 years of commercial and launch experience.
- Jones's expertise expected to aid in the commercialization of ANX005 and ANX007.
- Previous successful product launches include major brands like Nurtec® ODT, Abilify®, and Farxiga®.
- Potential concerns about continuity and experience gaps due to new board member transition.
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operations
BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of William “BJ” Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry.
“We are thrilled to add BJ to our board of directors at this transformative time for Annexon,” said Douglas Love, president and chief executive officer of Annexon. “His deep commercial expertise and proven experience in scaling large organizations and executing commercialization strategies for novel medicines will be invaluable as ANX005 for Guillain-Barré Syndrome and ANX007 for geographic atrophy approach commercialization.”
Mr. Jones added, “Annexon is leading the development of first-in-kind upstream complement medicines with significant opportunities across neuroinflammatory diseases that have yet to be unlocked. I look forward to partnering with Annexon and the board to support them in their mission to deliver a new era of complement targeted therapies.”
Mr. Jones joins Annexon with demonstrated commercial success at both large pharmaceutical and small biotechnology companies, with particular experience in driving mass-market product launch strategies for industry-leading brands. He currently serves as chief commercial officer of NewAmsterdam Pharma Company N.V. where he leads all commercial functions, including marketing, market access, sales, medical science engagement and commercial operations. Previously Mr. Jones was the chief commercial officer, migraine & common diseases at Biohaven Pharmaceuticals, which was acquired by Pfizer for
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is harnessing classical complement-driven neuroinflammation to advance potentially first-in-kind treatments for millions of people living with serious neuroinflammatory diseases of the body, brain and eye. Our novel scientific approach focuses on C1q, the initiating molecule of classical complement’s potent inflammatory pathway that when misdirected can lead to tissue damage and loss. By targeting C1q, our immunotherapies are designed to stop neuroinflammatory diseases where they start. Our pipeline spans three diverse therapeutic areas – autoimmune, neurodegenerative and ophthalmic diseases – and includes targeted investigational drug candidates designed to address the unmet needs of over 8 million people worldwide. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the company’s ability to achieve regulatory approvals for its product candidates; the company’s ability to commercialize its product candidates, if approved; and continuing advancement of the company’s portfolio. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: the company’s history of net operating losses; the company’s ability to obtain necessary capital to fund its clinical programs; the early stages of clinical development of the company’s product candidates; the effects of public health crises on the company’s clinical programs and business operations; the company’s ability to obtain regulatory approval of and successfully commercialize its product candidates; any undesirable side effects or other properties of the company’s product candidates; the company’s reliance on third-party suppliers and manufacturers; the outcomes of any future collaboration agreements; and the company’s ability to adequately maintain intellectual property rights for its product candidates. These and other risks are described in greater detail under the section titled “Risk Factors” contained in the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
Who is the new board member appointed by Annexon (ANNX)?
What is the experience of William “BJ” Jones in the biotechnology industry?
What impact might William “BJ” Jones have on Annexon (ANNX)?
Which therapies are approaching commercialization at Annexon (ANNX)?
What is William “BJ” Jones's current role outside of Annexon (ANNX)?
What are some of the major brands William “BJ” Jones has helped launch?
What educational background does William “BJ” Jones have?
